Prognostic role of asymmetric dimethylarginine following coronary angiography and percutaneous coronary intervention: current evidence, limitations, and future directions
Year: 2026
Type: article
Study design: Systematic Review
Abstract: Background. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase and a candidate marker of impaired endothelial nitric oxide signaling. Despite procedural advances, coronary artery disease (CAD) remains associated with residual risk after invasive investigation and revascularization. Objective. To critically synthesize evidence linking circulating ADMA to coronary anatomy, plaque characteristics, cardiovascular outcomes, and restenosis in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI), with special attention to type 2 diabetes mellitus (T2DM). Evidence synthesis. In a meta-analysis of nine prospective CAG/PCI studies (6,374 participants), high versus low ADMA was associated with all-cause mortality (adjusted pooled RR 2.11, 95% CI 1.38–3.21), cardiovascular mortality (2.95, 1.14–7.68), major adverse cardiovascular events (2.10, 1.35–3.27), and restenosis (4.57, 2.52–8.30) [13]. However, other prospective cohorts yielded weaker or null associations for recurrent cardiovascular events [24], and findings vary by population, endpoint, kidney function, and analytical method [14–16,19]. A 2023 optical coherence tomography study associated higher ADMA with plaque vulnerability and subsequent events after PCI [12]. Conclusions. ADMA is a biologically credible research biomarker and frequently correlates with adverse prognosis, but independent association is not synonymous with improved prediction or actionable clinical benefit. Contemporary, assay-standardized, externally validated studies in defined PCI populations, particularly patients with T2DM, are needed.
Authors: Shamansurova, Z., Kalandarova, G.
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: asymmetric dimethylarginine, coronary artery disease, percutaneous coronary intervention, coronary angiography, restenosis, endothelial dysfunction, nitric oxide signaling, type 2 diabetes, cardiovascular mortality, major adverse cardiovascular events, plaque vulnerability, prognostic factors
Open Access status: green
OpenAlex ID: W7225866326
